First Time Loading...

Molecular Partners AG
SIX:MOLN

Watchlist Manager
Molecular Partners AG Logo
Molecular Partners AG
SIX:MOLN
Watchlist
Price: 3.225 CHF -3.73%
Updated: May 7, 2024

Molecular Partners AG
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Molecular Partners AG
Operating Income Peer Comparison

Comparables:
ADCT
CRSP
BSLN
IDIA
KURN

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Molecular Partners AG
SIX:MOLN
Operating Income
-CHf61.1m
CAGR 3-Years
-2%
CAGR 5-Years
-10%
CAGR 10-Years
N/A
ADC Therapeutics SA
NYSE:ADCT
Operating Income
-$166m
CAGR 3-Years
9%
CAGR 5-Years
-6%
CAGR 10-Years
N/A
CRISPR Therapeutics AG
NASDAQ:CRSP
Operating Income
-$222.5m
CAGR 3-Years
14%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
Basilea Pharmaceutica AG
SIX:BSLN
Operating Income
CHf19.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Idorsia Ltd
SIX:IDIA
Operating Income
-CHf803m
CAGR 3-Years
-19%
CAGR 5-Years
-152%
CAGR 10-Years
N/A
Kuros Biosciences AG
SIX:KURN
Operating Income
-CHf8.7m
CAGR 3-Years
9%
CAGR 5-Years
9%
CAGR 10-Years
N/A

See Also

What is Molecular Partners AG's Operating Income?
Operating Income
-61.1m CHF

Based on the financial report for Dec 31, 2023, Molecular Partners AG's Operating Income amounts to -61.1m CHF.

What is Molecular Partners AG's Operating Income growth rate?
Operating Income CAGR 5Y
-10%

The average annual Operating Income growth rates for Molecular Partners AG have been -2% over the past three years , -10% over the past five years .